anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The first group (Group A) will be considered the control group in which patients will undergo gastro-entero anastomosis. The anastomosis will be pre-colic, along the posterior wall of the stomach with the length of at least 5 cm. The first jejunal loop approximately 40 cm from the angle of Treitz will be used. The anastomosis can be performed manually or with staplers.

The second group (group B) will be considered the intervention group in which patients will undergo gastric partitioning plus gastro-entero anastomosis. The gastric partitioning is done 5 cm proximal to the lesion along the greater curvature towards the lesser curvature above the incisura using linear cutting stapler. The partitioning is performed horizontally and preserve a narrow tunnel along the lesser curvature that is calibrated with a orogastric tube gauge 32. Subsequently, a pre-colic gastro-entero anastomosis is performed in the proximal gastric chamber created by the partitioning. The anastomosis is done along the posterior wall, with at least 5 cm of length using the first jejunal loop approximately 40 cm from the angle of Treitz. The anastomosis can be performed manually or with staplers.
The invention relates to a nerve repair material and conduit that contain white jelly fungus polysaccharide. The material comprises a substrate, which is made of a bio-compatible and/or bio-decomposable polymer material. The substrate has a surface coated or grafted with white jelly fungus polysaccharide having a thickness of 0.1-10 μm. The material can be used to make a nerve conduit. Alternatively, the conduit made of polymer material is added with a plurality of composite nano-particles made of white jelly fungus polysaccharide and at least one positive-charge polysaccharide, wherein the white jelly fungus polysaccharide of the nano-particles takes a weight percentage of 20%-80% (w/w) of the total weight of the nano-particles and the nano-particles have a particles diameter of 30-300 nm. The polymer material is selected from polylactide, poly-(lactide-co-olycolide), polyglycolide, and copolymer of polylactide and polycaprolactone. The white jelly fungus polysaccharide has a molecular weight of 500-5,000 kDa. The nerve repair conduit that contains white jelly fungus polysaccharide effectively enhances repair and regeneration of damaged nerves.
Adult patients (≥ 18 years of age) with type 2 diabetes which are diagnosed under ICD-10 coding of E-11 were included in this study. The inclusion criteria are patients with primary diagnosis of E11and have visited the clinic at least twice with a complete record of glucose, uric acid, lipid and kidney profile. Participants were grouped into 2 groups - good and poor glycemic control based on their glycated hemoglobin (HbA1c) levels. Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c \< 7.0.

Data such as age, sex, ethnic, education, BMI, glucose, uric acid, lipid, and kidney profile as well as comorbidities and type of drug used were collected from the patients' medical records. Comorbid conditions were defined as either concomitant hypertension, dyslipidemia, chronic kidney disease, hyperuricemia, or combinations of them as diagnosed in the medical records. Diabetic complications of interest include macrovascular (heart disease, stroke), microvascular (nephropathy, retinopathy, neuropathy) and a combination of both as well as infection (urinary tract infection, pneumonia). These complications were also based on the medical records. Management modalities included were lifestyle modification, use of oral antidiabetic medications or insulin, or both.
We describe a new technology for producing eggs containing recombinant proteins based on the novel use of avian adenoviruses (AAV). Adenovirus infected embryonated eggs are used as the host organism. The proteins synthesized are isolated in high amounts per egg and purified excluding time-consuming steps of purification. As far as is known, the mechanisms of translation and post-translational modification of proteins in avian species fully resembles those of other higher eukaryotes such as humans, veterinary animals, and plants. In contrast with bacterial, yeast and plant host system s for producing recombinant proteins, avian embryos allow isolation of protein s in biologically active form free of endotoxins. The combination of high productivity and possibility of obtaining proteins in native form makes the system a unique choice for biotechnology, much more favorable than other hosts currently being used for this purpose.
The invention relates to biotechnology. A protein-polypeptide having antihypoxic and tissue-specific reparative activity on the nervous system is prepared from nerve tissue of the embryos of ungulate livestock during gestation from the middle of the first trimester to the middle of the last trimester of pregnancy by homogenization in a buffer solution with simultaneous extraction in the presence of reversible proteolysis inhibitors and non-ionic detergents at a pH of 5.2-8.5. The resultant homogenate is centrifuged and filtered. The proteins and peptides are isolated on a chromatography column with an anion exchange medium. The resultant fractions are combined and subjected to sterilizing filtration. The complex comprises negatively charged, weakly acidic, neutral proteins and polypeptides with molecular masses of from 0.5 to 200 kDa. The pharmaceutical composition comprises, as active ingredient, a complex with a concentration of 0.05-2.0 mg/ml and a polynucleotide fraction in the form of a sodium salt of deoxyribonucleic acid, as well as a pharmaceutically acceptable diluent.
Climate warming is seeing temperatures breach exceptional thresholds as the frequency and intensity of heat waves increase. Efforts to forecast species vulnerability to climate warming often focus on upper thermal limits threatening survival, overlooking the role of intraspecific variation in determining vulnerability. Using an estuarine fish (black bream, Acanthopagrus butcheri) as a model, we explore how intraspecific variation in body mass and among populations affects upper thermal tolerance. Upper thermal limits were quantified using critical thermal maxima (CTmax) of wild fish. We used a ∼500 g (mean = 52.4 g, range = 0.57-541 g) mass range to test the relationship between body mass and thermal tolerance. Four distinct black bream populations were chosen along a 5° latitudinal cline to explore population differences in thermal limits. Contrary to expectations, there was no effect of body mass on upper thermal limits. However, significant population differences in thermal tolerance were observed that correlate with mean habitat temperatures. Specifically, the southern population had a significantly lower CTmax (35.57 ± 0.43 °C) compared to northern (36.32 ± 0.70 °C) and mid-latitude (36.36 ± 1.15 °C) populations. These data underscore the importance of observing intraspecific variation in thermal limits to reveal the capabilities of individuals within a species to cope with climate warming and improve the management of at-risk life stages and populations.
PROBLEM TO BE SOLVED: To make it possible to effectively prevent the smell of feces simply by injecting a froth and smell suppressing agent into the pots of simple toilets, the portable type toilets used in automobiles, etc., or the toilets of general homes by incorporating fatty acid soap and deodorant into this agent. SOLUTION: This froth and smell suppressing compsn. contains the fatty acid soap and the deodorant. Such smell suppressing compsn. is finely foamed, therefore, if such froth and smell suppressing compsn. is injected into malodorous sources, for example, the feces, the fine froth envelopes the feces. Since the deodorant derived from the froth and smell suppressing compsn. is eventually incorporated into the froth, the malodorous gases dissipated from the malodorous sources, for example, the feces are changed to odorless components by reacting with this deodorant. The dissipation of the malodorous gases from the malodorous sources, for example, the feces, does not, therefore, arise and the smell is effectively suppressed. Then, if the compsn. is injected into the pots, the leaking smell of the feces is effectively prevented.
Chondral knee lesions are frequent and produce important functional limitations and arthrosis development. Arthrosis is one of the most important causes of disability and its treatment with prosthetic surgery is associated with a high cost, and is not free of other complications. Several studies of cell therapy with autologous chondrocytes have shown efficacy in the treatment of this type of lesions, and currently is a common technique for the treatment of focal lesions of articular cartilage. Autologous chondrocyte transplant is associated with morbidity of the cartilage sample removal, which needs intra-articular surgery, and the limited tissue sample for culture. Adipose tissue-derived mesenchymal stem cells (ASC) have demonstrated chondrocytic differentiation and have been used in animal models for articular cartilage repair. Adipose tissue yields more ASC than chondrocytes are obtained from cartilage, and liposuction is simple and with less adverse events than arthroscopy. It is worth mentioned that culture conditions are less stringent for ASC than for chondrocytes, in terms of number of passages to obtain the amount of cells needed for implantation.

We propose a randomized clinical trial, in which we compare the surgical implantation of either autologous chondrocytes or autologous ASC to treat chondral knee lesions.
The present invention belongs to the technical field of medicines. Disclosed are use of rhamnose in preparing a medicament for treating or preventing neurodegenerative diseases, a pharmaceutical composition, and use thereof. The present invention provides use of rhamnose or a hydrate thereof in preparing a medicament for treating or preventing neurodegenerative diseases. On the basis of the described use, a composition for treating or preventing neurodegenerative diseases is provided. The composition comprises rhamnose and/or a hydrate thereof, a cinnamic acid derivative or a pharmaceutically acceptable salt thereof, and a flavonoid compound. The composition can significantly improve the cognitive behavior of mice and can be used for treating or preventing neurodegenerative diseases.
Zanaflex is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Clinical studies of Zanaflex did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Cross-study comparison of pharmacokinetic data following single dose administration of 6 mg Zanaflex showed that younger subjects cleared the drug four times faster than the elderly subjects. In elderly patients with renal insufficiency (creatinine clearance < 25 mL/min), tizanidine clearance is reduced by more than 50% compared to healthy elderly subjects; this would be expected to lead to a longer duration of clinical effect. During titration, the individual doses should be reduced. If higher doses are required, individual doses rather than dosing frequency should be increased. Monitor elderly patients because they may have an increased risk for adverse reactions associated with Zanaflex.
Proteinuria is a major risk factor for progression to end-stage renal disease in both diabetic and nondiabetic nephropathies. Angiotensin II and aldosterone are the key players in the development of renal failure, either directly by promoting tissue fibrosis or indirectly through their action on glomerular hemodynamic and proteinuria. Therefore, pharmacological inhibition of the renin-angiotensin-aldosterone system (RAAS) may have a beneficial impact on proteinuria and chronic kidney diseases progression. Recently, renin inhibitors, a new class of drugs that selectively inhibits angiotensin II formation at the first step of the RAAS cascade has been introduced to clinical practice. Aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of hypertension. Blood pressure (BP)-lowering effect of aliskiren is associated with a decreased generation of angiotensin I, as it blocks its generation from angiotensinogen, by inhibiting the active enzymatic site of renin. The investigators plan this study to evaluate the short-term effects of treatment with aliskiren to those of placebo and ACEI perindopril on proteinuria.
Superior ophthalmic vein thrombosis is a rare condition scarcely described in clinical literature with potentially severe consequences including permanent vision loss. This report details the case of a 70-year-old woman who presented with acute binocular horizontal diplopia, relative proptosis of the OD by 4 mm, and pain OD. On exam, visual acuity was 20/20 OD and 20/30 OS with full extraocular movements. CT revealed proptosis OD with a thrombosed superior ophthalmic varix. Evaluation for etiology of hypercoagulability was unremarkable, although the patient did have an asymptomatic COVID-19 infection 1 month prior. To the authors' knowledge, this is the first reported case of superior ophthalmic vein thrombosis secondary to an asymptomatic COVID-19 infection.
<P>PROBLEM TO BE SOLVED: To provide a method for diagnosing and treating cancers related to a tumor suppressor designated as TS10q23.3.  <P>SOLUTION: The isolated polypeptide has a specific amino acid sequence encoding the tumor suppressor. The monoclonal antibody is immunologically bound to the tumor suppressor. A hybridoma cell produces the monoclonal antibody. The isolated nucleic acid or its complement contains a region encoding the tumor suppressor, its allele variant or mutant. The method for diagnosing cancers comprises a process for assaying the expression of the tumor suppressor. The method for treating cancers comprises a process for bringing a tumor cell into contact with the tumor suppressor under conditions to take in the tumor suppressor by the tumor cell.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The neuroinflammation is a crucial component of virtually all neurodegenerative disorders, including Alzheimer's disease (AD). The bacterial lipopolysaccharide (LPS), a potent activator of the innate immune system, was suggested to influence or even trigger the neuropathological alterations in AD. LPS-induced neuroinflammation involves changes in transcription of several genes, thus controlling these molecular processes may be a potentially efficient strategy to attenuate the progression of AD. Since genome-wide association studies showed that the majority of AD-related genetic risk factors (AD-GRF) are connected to the immune system, our aim was to identify AD-GRF affected in the hippocampus by LPS-induced systemic inflammatory response (SIR). Moreover, we analysed the role of bromodomain and extraterminal domain (BET) proteins, the readers of the acetylation code, in controlling the transcription of selected AD-GRF in the brain during neuroinflammation. In our study, we used a mouse model of LPS-induced SIR and mouse microglial BV2 cells. JQ1 was used as an inhibitor of BET proteins. The level of mRNA was analysed using microarrays and qPCR. Our data demonstrated that among the established AD-GRF, only the expression of Cd33 was significantly upregulated in the hippocampus during SIR. In parallel, we observed an increase in the expression of Brd4, a BET family member. JQ1 prevented an LPS-evoked increase in Cd33 expression in the hippocampus of mice. Moreover, JQ1 reduced Cd33 expression in BV2 microglial cells stimulated with blood serum from LPS-treated mice. Our study suggests that LPS-evoked SIR may increase Cd33 gene expression in the brain, and inhibition of BET proteins through suppression of Cd33 expression could be a promising strategy in prevention or in slowing down the progression of neuroinflammation and may potentially affect the pathomechanism of AD.
SIGNIFICANCE AND PURPOSE: Timely access to primary healthcare is one cornerstone of strong primary healthcare. Across Canada, timely access remains a significant challenge. One of the most highly recommended models around the world to improve timely access is advanced access (AA). Over the last two decades, AA has become increasingly popular in Canada. AA model has been widely promoted by the College of Family Physicians of Canada and several other provincial organizations and professional associations. Some tools to support the implementation of AA to PHC providers and practices have been developed such as workbook by Health Quality Ontario and Doctor of BC. However, those tools are important assets to initiate a reflection to improve, they are often not sufficient. Eight PHC teams interested in improving and expanding the implementation of AA have been coached through several PDSA cycles. However, the personalized support model used is very demanding in terms of capacity and resources. These findings guided the research team in developing and evaluating a Continuous Quality Improvement (CQI) Cohort program on advanced access to support Primary healthcare (PHC) teams.This study aims to develop knowledge on an externally facilitated CQI pan-Canadian cohort program that could potentially be transferred to provincial organizations or professional associations wishing to support clinics in quality improvement projects.

OBJECTIVE: Assess the effectiveness of CQI cohorts on AA outcomes.

QI INTERVENTION PROGRAM: PHC teams will participate in an externally facilitated CQI program focusing on AA. The proposed program consists of cycle of three key activities; 1) Interprofessional reflective sessions and need prioritization, 2) Group mentoring and PDSA Cycles and 3) Cohort cross-learning exchange opportunities.

METHODS: This study will be based on the cluster-controlled trial of a CQI program of PHC teams on AA. 48 PHC teams from Quebec will participate to the externally facilitated CQI cohort intervention. Volunteer clinics from the intervention regions will receive the CQI intervention for 18 months. Intervention clinics will be matched to PHC clinics located in other regions to compose the control group. The match will be based on the clinic level (1 to 10, based on the number of patients registered and services offered. Clinics in the control group will receive an audit on a selection of AA indicators and will be offered the intervention 12 to 18 months following their recruitment. Data collection and analysis will include quantitative data based on a comprehensive assessment of both AA processes and outcomes. These will be measured through a self-reflective survey for PHC team members, EMR data and patients related outcomes questionnaire on access. Qualitative data based on semi-structured interviews with key stakeholders, observations of the CQI activities and analysis of plans of action of documents plan of action will take place.
Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.
The current international recommendations on energy requirements for children aged 6-24 months were established based on data from the Western populations. More human data of healthy children from the developing countries where the living conditions may not be as favourable for child growth and development would be needed to ascertain the validity of the global recommendation. The role of the doubly-labelled water (DLW) technique in measuring total daily energy expenditure to derive energy requirements for humans was also highlighted. Low and middle income countries in Asian countries have undergone the nutrition transition and malnutrition on both ends of the spectrum emerge as significant nutrition challenges during this critical period of growth. Unfortunately, data on body composition, i.e., the relative amounts of fat and lean or fat-free tissue which constitutes quality normal growth beyond anthropometric measurements are scarce. These data will also be needed to guide the infant and young child feeding (IYCF) recommendations for good nutrition and health and to prevent all forms of malnutrition in the region.

This project addressed the need to fill the information gap for the region, and potentially be included for making revision on energy requirement recommendations for infants and young children (IYC) for Asia and beyond. Building on the previous technical cooperation between institutions in Southeast and South Asia with the International Atomic Energy Agency (IAEA) on stable isotopic techniques for health and nutrition well-being, this project is a collaboration between IAEA, FAO Regional Office for Asia and The Pacific, and Mahidol University, Thailand to carry out the study on doubly-labeled water for assessment of total energy expenditure and body composition among infants and young children aged 6-23 months old. Thailand conducted a longitudinal study with participation from 4 other countries, namely, Pakistan, Philippines, Sri Lanka and Vietnam, in undertaking the same assessments in a cross-sectional design.
Two assessment visits will be conducted in order to evaluate functional visual performance in severely vision impaired subjects with RP and normally sighted subjects. Two visits will occur at week 0 and week 4 with functional vision assessments occurring at both visits in order to assess visit-to-visit variability. For the MLYMT, navigational vision will be assessed using each eye and binocularly at up to 6 different light levels (range 0.3 to 100 lux). Subjects will also perform the Multi-Luminance Shape Discrimination Test (MLSDT) which assesses near object recognition under different lighting levels. MLYMT and MLSDT performance will be evaluated together with Best Corrected Visual Acuity (BCVA), Visual Field (VF) and responses to visual function questionnaires. Subjects will be assigned to one of two cohorts based on presence or absence of RP in addition to BCVA performance.
The invention relates to the technical field of food processing, and especially relates to essence oil microcapsules and a preparation method thereof. The essence oil microcapsules are composed of the following materials: wall materials, a first emulsifier, a stabilizer, and buffer salt. The core of the essence oil microcapsules is composed of the following materials: core materials, and a second emulsifier. The wall materials are composed of the following components: a component A and a component B; the component A is maltodextrin and/or malt syrup; and the component B is whey protein isolate and/or soy protein isolate. The preparation method of the essence oil microcapsules is capable of obviously raising the oil contents of the essence oil microcapsules; and the oil contents of the prepared essence oil microcapsules can be up to 23-35% while the embedding rates are 90% or higher. The preparation method is simple in technology, and low in cost; moreover, the preparation conditions can be easily controlled. The prepared essence oil microcapsule products have good stability, as well as good solubility and dispersion performance. Thus, the essence oil microcapsules can be widely applied in the industries, including the health-care product industry, the pharmaceutical industry, and so on.